Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis: The Antelope Phase 3 Randomized Clinical Trial

IMPORTANCE: Proposed biosimilar natalizumab (biosim-NTZ) PB006 is the first biosimilar monoclonal antibody therapy developed for multiple sclerosis (MS) treatment. OBJECTIVE: To evaluate matching efficacy, safety, and immunogenicity between biosim-NTZ and reference natalizumab (ref-NTZ) in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Hemmer, Bernhard, Wiendl, Heinz, Roth, Karsten, Wessels, Hendrik, Höfler, Josef, Hornuss, Cyrill, Liedert, Bernd, Selmaj, Krzysztof
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871944/
https://www.ncbi.nlm.nih.gov/pubmed/36689214
http://dx.doi.org/10.1001/jamaneurol.2022.5007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871944/
https://www.ncbi.nlm.nih.gov/pubmed/36689214
http://dx.doi.org/10.1001/jamaneurol.2022.5007

Ejemplares similares